TY - JOUR
T1 - Oral anti-tuberculosis drugs
T2 - An urgent medication reconciliation at hospitals in Indonesia
AU - Herawati, Fauna
AU - Fahmi, Eka Yuliantini
AU - Pratiwi, Noer Aulia
AU - Ramdani, Dewi
AU - Jaelani, Abdul Kadir
AU - Yulia, Rika
AU - Andrajati, Retnosari
N1 - Publisher Copyright:
© the Author(s), 2021.
PY - 2021/6/24
Y1 - 2021/6/24
N2 - Background: Four oral anti-tuberculosis drugs are conceived to be the most effective ones to eradicate Mycobacterium tuberculosis bacteria and to obviate the resistant organisms. However, the patients’ adherence and medication discrepancies are obstacles to achieving the goal. This study aimed to define the anti-tuberculosis drugs used in the hospitals and to detect the discrepancies in the continuity of the tuberculosis treatment. Design and Methods: This retrospective cross-sectional study was based on medical records of adult patients, and was conducted in two district tertiary care hospitals. Only 35 out of 136 patient records from Hospital A and 33 out of 85 records from Hospital B met the inclusion criteria. Results: The most common systemic anti-infective drugs in the study were ceftriaxone (51.80 DDD/100 patient-days) used in Hospital A and isoniazid (59.53 DDD/100 patient-days) used in Hospital B. The number of rifampicin prescriptions was less than that of isoniazid. Each patient received an average of two DDD/100 patient-days, which is an under dosage for an effective treatment. Conclusion: This study showed a medication discrepancy of tuberculosis therapy. Tuberculosis patients’ medical histories are not under the full attention of treating physicians wherever they are admitted. Thus, medication reconciliation is needed to accomplish the goal of a Tuberculosis-free world in 2050.
AB - Background: Four oral anti-tuberculosis drugs are conceived to be the most effective ones to eradicate Mycobacterium tuberculosis bacteria and to obviate the resistant organisms. However, the patients’ adherence and medication discrepancies are obstacles to achieving the goal. This study aimed to define the anti-tuberculosis drugs used in the hospitals and to detect the discrepancies in the continuity of the tuberculosis treatment. Design and Methods: This retrospective cross-sectional study was based on medical records of adult patients, and was conducted in two district tertiary care hospitals. Only 35 out of 136 patient records from Hospital A and 33 out of 85 records from Hospital B met the inclusion criteria. Results: The most common systemic anti-infective drugs in the study were ceftriaxone (51.80 DDD/100 patient-days) used in Hospital A and isoniazid (59.53 DDD/100 patient-days) used in Hospital B. The number of rifampicin prescriptions was less than that of isoniazid. Each patient received an average of two DDD/100 patient-days, which is an under dosage for an effective treatment. Conclusion: This study showed a medication discrepancy of tuberculosis therapy. Tuberculosis patients’ medical histories are not under the full attention of treating physicians wherever they are admitted. Thus, medication reconciliation is needed to accomplish the goal of a Tuberculosis-free world in 2050.
KW - Defined daily dose (DDD)
KW - Drug treatment
KW - Drug utilization study
KW - Infection (lung disease)
KW - Medication reconciliation
KW - Prevention/control program
KW - Tuberculosis drug
UR - http://www.scopus.com/inward/record.url?scp=85112784282&partnerID=8YFLogxK
U2 - 10.4081/jphr.2021.1896
DO - 10.4081/jphr.2021.1896
M3 - Article
AN - SCOPUS:85112784282
SN - 2279-9028
VL - 10
JO - Journal of Public Health Research
JF - Journal of Public Health Research
IS - 3
M1 - 1896
ER -
